Roche submits Avastin for second-line breast cancer

Roche (SIX:ROG; OTCQX:RHHBY) said it submitted an sBLA to FDA on July 16 for Avastin bevacizumab in combination with chemotherapy for second-line treatment of metastatic HER2-negative breast cancer based on the Phase III RIBBON2 trial. On Tuesday, FDA's Oncologic Drugs Advisory Committee voted 12-1 to recommend removing the first-line treatment of HER2-negative metastatic breast cancer indication from the label of the humanized mAb against VEGF. ...